Retrospective analysis identifies genomic biomarkers as crucial for survival predictions in Waldenström macroglobulinemia treatment, indicating refined risk assessment is needed.
Key Points
Overall survival is best predicted by rIPSSWM in non-BTKi patients, while models struggled in BTKi cohorts.
MYD88 mutations confer favorable prognosis exclusively with BTKi treatment, which alters survival predictions significantly.
Assessment using Sanger sequencing and next-generation sequencing revealed critical mutation patterns for prognostic value.
Molecular profiling underscores the need for tailored risk assessments in the era of targeted therapies.